Search
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalThis combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications … Berahyaluronidase alfa is a recombinant variant of human hyaluronidase designed to enhance dispersion and permeation of subcutaneously co-administered drugs.
Resmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalOn March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation.[L50336]
Tadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment
Categories: Antihypertensives for Pulmonary Arterial HypertensionProducts: LUDIKA TABLETAS RECUBIERTAS POR 20 MGOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [L44256] IDH1 mutations are common in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and myelodysplastic syndromes (MDS), and they lead to an increase
Selegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedIt may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Antidepressive Agents Indicated for DepressionHelminth Infection
go.drugbank.com/conditions/DBCOND0082009Synonyms: Infection due to Class Cestoda and/or Class Trematoda and/or Phylum NemataOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters. … [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]
Procaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approvedIt is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
Mixtures: Sterile Concentrate For Cardioplegia InfusionCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCefapirin
go.drugbank.com/drugs/DB01139ApprovedVet approvedProduction for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseChloramphenicol
go.drugbank.com/drugs/DB00446ApprovedInvestigationalVet approvedWithdrawnIt has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. … An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically.
Mixtures: CLOXONA-OCategories: Antibiotics for Topical Use, Antibacterials for Systemic Use